BioSymetrics is a phenomics-driven drug discovery company that integrates clinical and experimental data, using machine learning, to translate human disease biology and advance precision medicines. We partner with leading healthcare and life science companies, such as Northwell Health, Janssen, Sema4, and Mt. Sinai, to increase our understanding of disease and find better drugs faster. We use a patent pending, machine learning technology called Contingent-AI™ to address bias detection and correction during pre-processing stages of machine learning and identify additional feature sets for analysis that are contingent upon decisions made during bias reduction. We combine this technology with an experimental practice that uniquely combines in silico and in vivo work to produce a faster, more precise set of predictive results for drug discovery research. We are a remote-first company with people clusters in Toronto and Boston. We are actively hiring. For more information, please visit our website at www.biosymetrics.com. #ArtificialIntelligence #AI #MachineLearning #Biotech #Healthcare #DataAnalytics #BigData #PrecisionMedicine #Pharma #LifeSciences #Genomics #DigitalHealth #DrugDiscovery #MedTech
Location: United States, Massachusetts, Boston
Member count: 11-50
Founded date: 2015
Investors 2
Date | Name | Website |
- | Plug and P... | plugandpla... |
- | Dasein Cap... | daseincap.... |
Mentions in press and media 2
Date | Title | Description | Category | Author | Source |
09.11.2022 | John Baldo... | BioSymetrics, a phenomics-driv... | - | - | aithority.... |
29.10.2019 | BioSymetri... | – First biomedical machine lea... | - | Jasmine Pe... | hitconsult... |